Patent foramen ovale: Where are we in 2009?

American Journal of Therapeutics

Volumn 16, Issue 6, 2009, Pages 562-572

  Sommer, Robert J ^a  

^a Medical Center ^*  (United States)

Author keywords

Congenital heart disease; Interventional catheterization; Migraine headache; Patent Foramen Ovale; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

ALTITUDE DISEASE; ANTICOAGULANT THERAPY; CONGENITAL HEART MALFORMATION; DECOMPRESSION SICKNESS; DISEASE ASSOCIATION; DIVER; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM SEPTUM; HUMAN; HYPOXEMIA; LUNG EDEMA; MIGRAINE; MORBIDITY; PATENT FORAMEN OVALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RADIOFREQUENCY; REVIEW; RISK ASSESSMENT; SLEEP APNEA SYNDROME; SURGICAL INSTRUMENT; SURGICAL TECHNIQUE; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT OUTCOME;

FORAMEN OVALE, PATENT; HUMANS; MIGRAINE DISORDERS; SLEEP APNEA SYNDROMES; STROKE;

EID: 74549158811     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318197eaef     Document Type: Review

References (83)

1. Moore KL, Persuad TVN. The cardiovascular system. In: The Developing Human: Clinically Oriented Embryology. 7th ed. Philadelphia, PA: Saunders; 2003:329-379.
2. Gentile R, Stevenson G, Dooley T, et al. Pulsed Doppler echocardiographic determination of time of ductal closure in normal newborn infants. J Pediatr. 1981;98:443-448.
3. Anderson RH, Brown NA, Webb S. Development and structure of the atrial septum. Heart. 2002;88:104-110.
4. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clinic Proc. 1988;59:17-20.
5. Patten BM. The closure of the foramen ovale. Am J Anat. 1931;48:19-44.
6. Konstadt SN, Louie EK, Black S, et al. Intraoperative detection of patent foramen ovale by transesophageal echocardiography. Anesthesiology. 1991;74:212-216.
7. Fisher DC, Fisher EA, Budd JH, et al. The incidence of patent foramen ovale in 1,000 consecutive patients. A contrast transesophageal echocardiography study. Chest. 1995;107:1504-1509.
8. Lechat P, Mas JL, Lascault G, et al. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med. 1988; 318:1148-1152.
9. WebsterMW, ChancellorAM, SmithHJ, et al. Patent foramen ovale in young stroke patients. Lancet. 1988;8601:11-12.
10. Di Tullio M, Sacco RL, Gopal A, et al. Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med. 1992;117:461-465.
11. Ranoux D, Cohen A, Cabanes L, et al. Patent foramen ovale: is stroke due to paradoxical embolism? Stroke. 1993;24:31-34.
12. Lamy C, Giannesini C, Zuber M, et al. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Stroke. 2002;33:706-711.
13. Del Sette M, Angeli S, Leandri M, et al. Migraine with aura and right-to-left shunt on transcranial Doppler: a case-control study. Cerebrovasc Dis. 1998;8:327-330.
14. Anzola GP, Magoni M, Guindani M, et al. Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study. Neurology. 1999;52:1622-1625.
15. Sztajzel R, Genoud D, Roth S, et al. Patent foramen ovale, a possible cause of symptomatic migraine: a study of 74 patients with acute ischemic stroke. Cerebrovasc Dis. 2002; 13:102-106.
16. Wilmshurst P, Nightingale S. Relationship between migraine and cardiac and pulmonary right-to-left shunts. Clin Sci (Lond). 2001;100:215-220. (Pubitemid 32165366)
17. Wilmshurst P, Pearson M, Nightingale S. Re-evaluation of the relationship between migraine and persistent foramen ovale and other right-to-left shunts. Clin Sci (Lond). 2005; 108:365-367.
18. Torti SR, Billinger M, Schwerzmann M, et al. Risk of decompression illness among 230 divers in relation to the presence and size of patent foramen ovale. Eur Heart J. 2004;25:1014-1020.
19. Sloan MA, Alexandrov AV, Tegeler CH, et al. Assessment: transcranial Doppler ultrasonography: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2004; 62:1468-1481.
20. Spencer MP, Moehring MA, Jesurum J, et al. Power Mmode transcranial Doppler for diagnosis of patent foramen ovale and assessing transcatheter closure. J Neuroimaging. 2004;14:342-349.
21. Mohrs OK, Petersen SE, Erkapic D, et al. Dynamic contrastenhanced MRI before and after transcatheter occlusion of patent foramen ovale. Am J Roentgenol. 2007;188:844-849.
22. Dearani JA, Ugurlu BS, Danielson GK, et al. Surgical patent foramen ovale closure for prevention of paradoxical embolism-related cerebrovascular ischemic events. Circulation 1999;100(19 Suppl):II171-II175.
23. Bridges ND, HellenbrandW, Latson L, et al. Transcatheter closure of patent foramen ovale after presumed paradoxical embolism. Circulation. 1992;86:1902-1908.
24. Schuchlenz HW, Weihs W, Berghold A, et al. Secondary prevention after cryptogenic cerebrovascular events in patients with patent foramen ovale. Int J Cardiol. 2005;101: 77-82.
25. Hugl B, Klein-Weigel P, Posch L, et al. Peripheral ischemia caused by paradoxical embolization: an underestimated problem? Mt Sinai J Med. 2005;72:200-206. (Pubitemid 40668321)
26. Carano N, Agnetti A, Hagler DJ, et al. Acute myocardial infarction in a child: possible pathogenic role of patent foramen ovale associated with heritable thrombophilia. Pediatrics. 2004;114:e255-e258.
27. Steuber C, Panzner B, Steuber T, et al. [Open foramen ovale in patients with arterial vascular occlusions of the retina and optic nerve]. Ophthalmologe. 1997;94:871-876.
28. Shnaider H, Shiran A, Lorber A. Right ventricular diastolic dysfunction and patent foramen ovale causing profound cyanosis. Heart. 2004;90:e31.
29. Nagayoshi Y, Toyama K, Kawano H, et al. Platypneaorthodeoxia syndrome combined with multiple congenital heart anomalies. Intern Med. 2005;44:453-457.
30. Guerin P, Lambert V, Godart F, et al. Transcatheter closure of patent foramen ovale in patients with platypneaorthodeoxia: results of a multicentric French registry. Cardiovasc Intervent Radiol. 2005;28:164-168.
31. Ilkhanoff L, Naidu SS, Rohatgi S, et al. Transcatheter device closure of interatrial septal defects in patients with hypoxia. J Interv Cardiol. 2005;18:227-232
32. Godart F, Rey C, Prat A, et al. Atrial right-to-left shunting causing severe hypoxaemia despite normal right-sided pressures: Report of 11 consecutive cases corrected by percutaneous closure. Eur Heart J. 2000;21:483-489.
33. Rao PS, Palacios IF, Bach RG, et al. Platypnea-orthodeoxia: management by transcatheter buttoned device implantation. Catheter Cardiovasc Interv. 2001;54:77-82.
34. Waight DJ, Cao QL, Hijazi ZM. Closure of patent foramen ovale in patients with orthodeoxia-platypnea using the amplatzer devices. Catheter Cardiovasc Interv. 2000;50:195-198.
35. Landzberg MJ, Sloss LJ, Faherty CE, et al. Orthodeoxiaplatypnea due to intracardiac shunting-relief with transcatheter double umbrella closure. Cathet Cardiovasc Diagn. 1995;36:247-250.
36. Kerstein D, Levy PS, Hsu DT, et al. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation. 1995;91:2028-2035.
37. Wilmshurst PT, Nightingale S, Walsh KP, et al. Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet. 2000;356:1648-1651.
38. Allemann Y, Hutter D, Lipp E, et al. Patent foramen ovale and high-altitude pulmonary edema. JAMA. 2006;296: 2954-2958.
39. Shanoudy H, Soliman A, Raggi P, et al. Prevalence of patent foramen ovale and its contribution to hypoxemia in patients with obstructive sleep apnea. Chest. 1998;113; 91-96.
40. Beelke M, Angeli S, Del Sette M, et al. Prevalence of patent foramen ovale in subjects with obstructive sleep apnea: a transcranial Doppler ultrasound study. Sleep Med. 2003; 4:219-223.
41. Johansson MC, Eriksson P, Peker Y, et al. The influence of patent foramen ovale on oxygen desaturation in obstructive sleep apnoea. Eur Respir J. 2007;29:149-155.
42. Agnoletti G, Iserin L, LaFont A, et al. Obstructive sleep apnea and patent foramen ovale: successful treatment of symptoms by percutaneous foramen ovale closure. J Interven Cardiol. 2005;18:393-395.
43. Lidegaard O. Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease. Br J Obstet Gynaecol. 1995;102:153-159.
44. Tzourio C, BousserMG.Migraine: a risk factor for ischemic stroke in young women. Stroke. 1997;28:2569-2570.
45. Carolei A, Marini C, De Matteis G. History of migraine and risk of cerebral ischaemia in young adults. The Italian National Research Council Study Group on Stroke in the Young. Lancet. 1996;347:1503-1506.
46. Kruit MC, van Buchem MA, Hofman PA, et al. Migraine as a risk factor for subclinical brain lesions. JAMA. 2004; 291:427-434.
47. Dowson A, Mullen MJ, Peatfield R, et al. Migraine Intervention With STARFlex Technology (MIST) Trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation. 2008; 117;1397-1404.
48. Reisman M, Christofferson RD, Jesurum J, et al. Migraine headache relief after transcatheter closure of patent foramen ovale. J Am Coll Cardiol. 2005;45:493-495.
49. Azarbal B, Tobis J, Suh W, et al. Association of interatrial shunts and migraine headaches: impact of transcatheter closure. J Am Coll Cardiol. 2005;45:489-492.
50. Morandi E, Anzola GP, Angeli S, et al. Transcatheter closure of patent foramen ovale: a new migraine treatment? J Interv Cardiol. 2003;16:39-42.
51. Schwerzmann M, Wiher S, Nedeltchev K, et al. Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks. Neurology. 2004;62:1399-1401. (Pubitemid 38526056)
52. Post MC, Thijs V, Schonewille WJ, et al. Embolization of pulmonary arteriovenous malformations and decrease in prevalence of migraine. Neurology. 2006;66; 202-205.
53. Rundek T, Elkind MSV, Di Tullio MR, et al. Patent foramen ovale and migraine: a cross-sectional study from the Northern Manhattan Study (NOMAS). Circulation. 2008;118:1419-1424.
54. Mauri L. Association between migraine headaches and patent foramen ovale: a large, case-control study. Paper presented at: American Heart Association Scientific Sessions; November 10, 2008; New Orleans, LA.
55. Braun M, Gliech V, Boscheri A, et al. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results of three different device occluder systems. Eur Heart J. 2004;25:424-430.
56. Krumsdorf U, Ostermayer S, Billinger K, et al. Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1000 consecutive patients. J Am Coll Cardiol. 2004;43:302-309.
57. Spies C, Strasheim R, Timmermanns I, et al. Patent foramen ovale closure in patients with cryptogenic thrombo-embolic events using the Cardia PFO occluder. Eur Heart J. 2005;27:365-371.
58. Spencer MP, Moehring MA, Jesurum J, et al. Power M-mode transcranial Doppler for diagnosis of patent foramen ovale and assessing transcatheter closure. J Neuroimaging. 2004;14:342-349.
59. Anzola GP, Morandi E, Casilli F, et al. Does transcatheter closure of patent foramen ovale really "shut the door?" A prospective study with transcranial Doppler. Stroke. 2004; 35:2140-2144.
60. Ruiz CE, Alboliras ET, Pophal SG. The puncture technique: a new method for transcatheter closure of patent foramen ovale. Catheter Cardiovasc Interv. 2001;53:369-372.
61. Onorato E, Melzi G, Casilli F, et al. Patent foramen ovale with paradoxical embolism: mid-term results of transcatheter closure in 256 patients. J Interv Cardiol. 2003;16: 43-50.
62. Martin F, Sanchez PL, Doherty E, et al. Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Circulation. 2002;106:1121-1126.
63. Wahl A, Krumsdorf U, Meier B, et al. Transcatheter treatment of atrial septal aneurysm associated with patent foramen ovale for prevention of recurrent paradoxical embolism in high-risk patients. J Am Coll Cardiol. 2005;45: 377-380.
64. Khositseth A, Cabalka AK, Sweeney JP, et al. Transcatheter Amplatzer device closure of atrial septal defect and patent foramen ovale in patients with presumed paradoxical embolism. Mayo Clin Proc. 2004;79:35-41.
65. Post MC, Van Deyk K, Werner B. Percutaneous closure of a patent foramen ovale: single-centre experience using different types of devices and mid-term outcome. Acta Cardiol. 2005;60:515-519.
66. Windecker S,Wahl A, Nedeltchev K, et al. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke. J Am Coll Cardiol. 2004;44:750-758. (Pubitemid 39099567)
67. SchuchlenzHW, Mannweiler S, Martin D. Marked foreign body reaction and thrombus formation after transcatheter closure of a patent foramen ovale. J Thorac Cardiovasc Surg. 2005;130:591-592.
68. Kiblawi F, Levchuck SG, Sommer RJ. Transcatheter closure of patent foramen ovale in older adults. Catheter Cardiovasc Interv. 2006;68:136-142.
69. Divekar A, Gaamangwe T, Shaikh N, et al. Cardiac perforation after device closure of atrial septal defects with the Amplatzer septal occluder. J Am Coll Cardiol. 2005;45:1213-1218.
70. Trepels T, Zeplin H, Sievert H, et al. Cardiac Perforation following transcatheter PFO closure. Catheter Cardiovasc Interv. 2003;58:111-113.
71. Ewert P, Kretschmar O, Peters B, et al. Preliminary Experience With a New 18 mm Amplatzer PFO Occluder for Small Persistent Foramen Ovale. Catheter Cardiovasc Interv. 2003;59:518-521.
72. Cecconi M, Quarti A, Bianchini F, et al. Late Cardiac Perforation After Transcatheter Closure of Patent Foramen Ovale. Ann Thorac Surg. 2006;81:e29-e30.
73. Taaffe M, Fischer E, Baranowski A, et al. Comparison of Three Patent Foramen Ovale Closure Devices in a Randomized Trial (Amplatzer Versus CardioSEAL-STARflex Versus Helex Occluder). Am J Cardiol. 2008;101:1353-1358.
74. Meier B. Iatrogenic Atrial Septal Defect, Erosion of the Septum Primum After Device Closure of a Patent Foramen Ovale as a New Medical Entity. Catheter Cardiovasc Interv. 2006;68:165-168.
75. Chun DS, Turrentine MW, Moustapha A, et al. Development of aorta-to-right atrial fistula following closure of secundum atrial septal defect using the Amplatzer septal occluder. Catheter Cardiovasc Interv. 2003;58:246-251.
76. Amin Z, Hijazi ZM, Bass JL, et al. Erosion of Amplatzer septal occluder device after closure of secundum atrial septal defects: review of registry of complications and recommendations to minimize future risk. Catheter Cardiovasc Interv. 2004;63:496-502.
77. Wilmshurst PT, Nightingale S, Walsh KP, et al. Clopidogrel reduces migraine with aura after transcatheter closure of persistent foramen ovale and atrial septal defects. Heart. 2005;91:1173-1175.
78. Ries MW, Kampmann C, Rupprecht HJ, et al. Nickel release after implantation of the Amplatzer occluder. Am Heart J. 2003;145:737-741.
79. Buscheck F, Sievert H, Kleber F, et al. Patent foramen ovale closure using the Premere device: the results of the CLOSEUP trial. J Interv Cardiol. 2006;19:328-333.
80. Jux C, Wohlsein P, Bruegmann M, et al. A new biological matrix for septal occlusion. J IntervCardiol. 2003;16:149-152.
81. Sievert H, Fischer E, Heinisch C, et al. Transcatheter closure of patent foramen ovale without an implant: initial clinical experience. Circulation. 2007;116:1701-1706.
82. Reiffenstein I, Majunke N, Wunderlich N, et al. Percutaneous closure of patent foramen ovale with a novel FlatStent. Expert Rev Med Devices. 2008;5:419-425.
83. Ruiz CE, Kipshidze N, Chiam PT, et al. Feasibility of patent foramen ovale closure with no-device left behind: first-in-man percutaneous suture closure. Catheter Cardiovasc Interv. 2008;71:921-926.